Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 36Carcinoma, Non-Small-Cell Lung 17Small Cell Lung Carcinoma 16Neoplasms 14Lung Neoplasms 13Breast Neoplasms 8Melanoma 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Glioblastoma 4Endometrial Neoplasms 4Recurrence 3Ovarian Neoplasms 3Neoplasms by Site 3Neoplasms by Histologic Type 3Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Osteosarcoma 2Mesothelioma, Malignant 2Mesothelioma 2

Interventions

atezolizumab 1Tomography, X-Ray Computed 1Endosonography 1Diet, Ketogenic 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Fatty Liver × atezolizumab × Clear all
NCT06096779 2026-06-01

Kirros

Genentech, Inc.

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡